Additionally, CDC induction plays important roles in alemtuzumab (CD52) therapy for leukemia and the combined therapy with trastuzumab and pertuzumab (anti-HER2/neu) for breast and gastric cancers41–43. This evidence concerns the gene CD52 and leukemia.